Despite advancements in treatment—including chemotherapy, targeted therapy with epidermal growth factor receptor antibodies, and immunotherapy with immune checkpoint inhibitors—many CRC cases exhibit intrinsic or acquired resistance to cancer treatment, leading to limited treatment efficacy and high recurrence rates. Here, EGFR is linked to colorectal carcinoma.